lead compound


Also found in: Wikipedia.

lead compound

A peptide, small molecule, or other agent with pharmacological or biochemical properties which suggest that it may have therapeutic potential and value as a starting point for drug development.
References in periodicals archive ?
DelMar Pharmaceutical announced that the Company anticipates that its current cash position, which includes the $6.7M in net proceeds from the underwritten offering completed August 16, will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 clinical trials for its lead compound, VAL-083, which the Company believes will occur by the Q4 of FY20.
Global Banking News-November 5, 2018-Acesion Pharma reports positive results from Phase 1 clinical trial of lead compound in cardioversion, AP30663
9,572,807) for NSI-189, the lead compound in the company's neurogenic small molecule program in development for the treatment of major depressive disorder.
for an upfront payment of USD 125m (subject to certain adjustments) and additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201, and certain backup compounds, the company said.
In pharmaceuticals, lead compound obviousness analysis usually involves analyzing the substitution of a portion of a structurally similar known compound to arrive at the claimed compound.
This approach is now commonly used in advance drug design to optimize lead compound by rational molecular modification in order to improve its pharmacokinetic i.e.
According to Toshimasa Yamauchi, a member of the research team and lecturer at the Graduate School of Medicine at the University of Tokyo, AdipoRon could become "a lead compound" in a possible oral treatment for diabetes.
They identified a new lead compound with nanomolar activity and low toxicity.
NBTXR3, the lead compound of Nanobiotix's NanoXray product pipeline, is a nanoparticle formulation of hafnium oxide crystals for the local treatment of tumors to enhance the efficiency of radiotherapy.
NephRx Corporation, Kalamazoo, MI, announced it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed its first subject in the study.
Its lead compound could have unique applications for the treatment of inflammatory diseases, including rheumatoid arthritis, Gilead said.